GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE

LOK SABHA
UNSTARRED QUESTION NO. 2180
TO BE ANSWERED ON 31ST JULY, 2026

DEMAND FOR DIALYSIS FACILITIES

2180. SHRI SANATAN PANDEY:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state**:**

(a) whether the Government is aware that the demand for dialysis facilities is increasing due to the rising number of patients suffering from kidney diseases in Uttar Pradesh, particularly in the Ballia Parliamentary Constituency;

(b) if so, the details of the dialysis machines and dialysis centres available in Government hospitals and other centres in the Ballia Parliamentary Constituency along with the number of patients who benefited during the last three years, year-wise;

(c) whether the Government has proposed any new scheme or project for the expansion of dialysis facilities and the prevention of kidney diseases, if so, the details thereof;

(d) the details of the number of cases of alleged deaths caused by spurious or adulterated cough syrups in the country and in Uttar Pradesh during the last three years, along with the status of investigations and the action taken by the Government against the persons found responsible in this regard; and

(e) the steps taken and proposed to be taken by the Government to strengthen the drug quality control and surveillance mechanism to prevent the recurrence of such incidents?

ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE
(SHRI PRATAPRAO JADHAV)

(a) to (c) 'Public Health' and 'Hospitals' are state subjects. However, the Government of India provides technical and financial support to the States/UTs under the National Health Mission (NHM) for strengthening healthcare infrastructure, including dialysis services.

Under NHM, the Ministry of Health and Family Welfare launched the Pradhan Mantri National Dialysis Programme (PMNDP) to improve access to haemodialysis services by establishing dialysis centres in District Hospitals across the country and providing free dialysis services to eligible patients. Under the Programme, the Ministry provides financial assistance to the States/UTs for establishment of dialysis centres based on the proposals submitted by them under their annual Programme Implementation Plans (PIPs), prepared on the basis of gap analysis.

The Programme is presently being implemented in all 36 States/UTs covering 751 districts (including 44 linked districts) through 1,856 haemodialysis centres equipped with 13,535 haemodialysis machines, as reported by the States/UTs as on 30.06.2026.

In the State of Uttar Pradesh, dialysis centres are functional in all 75 districts. The dialysis services are available in the Ballia Parliamentary constituency, at District Hospital Ballia having 16 functional haemodialysis machines under PMNDP. The service delivery is in PPP mode.

(d) & (e) CDSCO in coordination with State Drugs Controller, Uttar Pradesh conducted a joint investigation in Uttar Pradesh. Drug samples were drawn from the manufacturing premises under the provisions of Drugs & Cosmetics Act, 1940 for test & analysis. Further, manufacturing license of the firm was suspended and FIR lodged by State Licensing Authority, Uttar Pradesh on 09.01.2023.

CDSCO and Ministry of Health and Family Welfare have taken following regulatory measures to ensure the import and manufacture of safe, efficacious and quality medicines across the country:

(i) An advisory has been issued to all State/UT Health Departments and healthcare facilities to ensure rational use of paediatric cough syrups.

(ii) In addition to the existing requirements of testing the raw materials, the Indian Pharmacopoeia Commission, Ghaziabad has issued an amendment to Indian Pharmacopoeia (IP) 2022.

(iii) In order to assess the regulatory compliance of drug manufacturing premises in the country, the CDSCO along with State Drugs Controllers (SDCs) have conducted Risk-Based Inspections of more than 960 premises since December, 2022.

(iv) More than 1100 cough syrup manufacturers have been subjected to intense audit in coordination with State authorities. Increased market surveillance sampling of syrup formulations by Central and State drugs regulators has also been done.

(v) The Central Government has amended the Drugs Rules 1945 vide G.S.R. 922 (E) dated 28.12.2023 to revise the schedule M to the said rules related to Good Manufacturing Practices and requirements of premises, plant and equipment for pharmaceutical products.

(vi) CDSCO published regulatory guidelines for the sampling of drugs, cosmetics, and medical devices by Central and State Drugs Inspectors.

(vii) An online portal, SUGAM labs is in place since September 2023 for integrating the drug testing labs of the CDSCO.

(viii) The Drugs Rules, 1945 have been amended in year 2023 to mandate that manufacturers of the top 300 drug formulation brands listed in Schedule H2 shall print or affix a Bar Code or QR Code on the primary packaging label, or on the secondary label where space is insufficient.

(ix) Central regulator coordinates activities of State Drug Control Organisations and provides expert advice through the Drugs Consultative Committee (DCC) meetings.

(x) Central government is providing regular residential, regional training and workshops to officials of CDSCO and State Drug Regulatory Authorities on Good Manufacturing Practices.

*****